A bill was unveiled by Democrats this week in Congress to require rebates from drugmakers on prescription treatments used by beneficiaries of both Medicare Part D and Medicaid. Drugmakers say the plan would weaken Part D and amounts to "mandatory government price controls ... cleverly disguised as 'rebates.'" The measure "would bring higher premiums and co-pays, more restricted access to medicines for seniors and Americans with disabilities, and diminished research on the next generation of medicines," PhRMA Senior Vice President Matthew Bennett said.

Related Summaries